Contract Research Services

ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases.

As part of our ImQuest SUCCESS platform, we provide expert preclinical research services and compound screening to define the efficacy, mechanism of action and toxicity of pharmaceutical products and specialize in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines for infectious disease and cancer drug development programs.

We have expertise in research services for antiviral, antibiotic, and anticancer product development, in vitro toxicology assessment and pharmaceutical product characterization, analytical method development and formulation.

We are committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. Our team has decades of experience in the field of virology, microbiology and oncology. As such, we understand that each product and each client is unique and we strive to provide effective solutions. Learn More.

What's New

  • Virology Updates: Influenza and Yellow Fever on the Rise

    Influenza incidence on the rise, and yellow fever outbreak in Brazil highlight need for new antiviral therapies. Contact us to learn more about how we can assist your anti-infectious product development.

    Read More


  • Society of Toxicology -- Annual Meeting

    March 12-16, 2017
    Baltimore, MD
  • International Conference on Antiviral Research

    May 21-25, 2017

Meet the Team

Guy Pilkington, Ph.D.

Director, Molecular Virology and Hepatitis Research Services

Dr. Pilkington received his Ph.D. in Biochemistry, Molecular and Cellular Biology from the University of Arizona in 2008 working on the mechanisms regulating mRNA

Read More